ERBB2 and cancer: Therefore, it would be of great significance to further investigate the effect of targeting of DPAGT1 on HER2 shedding and trastuzumab resistance in HER2+ pancancer types, which might represent a promising strategy against trastuzumab-resistant HER2+ cancer.